{
    "eid": "2-s2.0-85080139615",
    "title": "Biologics for chronic rhinosinusitis",
    "cover-date": "2020-02-27",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Lee Yee Chong",
        "Patorn Piromchai",
        "Steve Sharp",
        "Kornkiat Snidvongs",
        "Carl Philpott",
        "Claire Hopkins",
        "Martin J. Burton"
    ],
    "citedby-count": 9,
    "ref-count": 150,
    "ref-list": [
        "Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: results from a phase 2a trial",
        "Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis",
        "Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids",
        "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial",
        "Dupilumab in chronic sinusitis with nasal polyposis, with and without asthma",
        "Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSWNP)",
        "Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis",
        "Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps",
        "The effect of dupilumab on biomarkers in the peripheral blood and nasal secretions in the treatment of chronic sinusitis with nasal polyposis",
        "Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial",
        "A randomised, double blind, placebo controlled, multi-centre study to investigate the use of mepolizumab (SB240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis",
        "Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis",
        "Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma",
        "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma",
        "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials",
        "Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 sinus-24 study",
        "A randomized phase 3 study, sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps",
        "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials",
        "Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma",
        "A randomized, double-blind, placebo-controlled clinical trial of omalizumab for chronic rhinosinusitis",
        "A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis",
        "Dupilumab improves outcomes of concurrent asthma and chronic sino-nasal conditions in patients with atopic dermatitis-a pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFE)",
        "Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study",
        "Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [Abstract]",
        "Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab",
        "Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps",
        "Nasal interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients",
        "Anti-interleukin-5 treatment in nasal polyposis",
        "Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis",
        "Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis",
        "Dupilumab improves all ACQ-5 individual items in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma: results from a phase 2a trial",
        "Dupilumab improves ACQ-5 items in CRSwNP patients with comorbid asthma",
        "Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD",
        "Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study",
        "Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in liberty asthma quest",
        "Dupilumab improves lung function and reduces severe exacerbation rate in patients with uncontrolled, moderate-to-severe asthma with or without comorbid allergic rhinitis: results from the phase 3 LIBERTY ASTHMA QUEST study",
        "Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma",
        "Dupilumab treatment produces rapid and sustained improvements in FEV1 in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study",
        "Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 liberty asthma quest study",
        "A randomized, controlled phase 3 study, LIBERTY ASTHMA QUEST, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma",
        "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma",
        "Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility",
        "Dupilumab suppresses inflammatory biomarkers in asthma patients with or without allergic rhinitis: post hoc analysis of the LIBERTY ASTHMA QUEST study",
        "Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma",
        "Dupilumab produces rapid and sustained improvements in asthma-related symptoms in patients with uncontrolled, moderate-to-severe asthma from the LIBERTY ASTHMA QUEST study",
        "Dupilumab improves asthma control and asthma-related quality of life in uncontrolled persistent asthma patients across all baseline exacerbation rates",
        "Dupilumab improves asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbation history",
        "Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in liberty asthma quest",
        "Dupilumab efficacy in severe asthma exacerbations by different baseline patient characteristics in patients with uncontrolled persistent asthma",
        "Dupilumab improves asthma outcomes regardless of baseline lung function",
        "Dupilumab efficacy and effect on asthma control in patients with uncontrolled persistent asthma and comorbid chronic rhinosinusitis with or without nasal polyps",
        "Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis",
        "Dupilumab improved asthma control in patients with uncontrolled, moderate-to-severe asthma, regardless of exacerbations in the previous year",
        "Dupilumab improves health related quality of life in uncontrolled, moderate-to-severe asthma patients with comorbid allergic rhinitis from the phase 3 LIBERTY ASTHMA QUEST study",
        "Dupilumab suppresses type 2 biomarkers in asthma patients with and without comorbid chronic rhinosinusitis with or without nasal polyposis (CRS/NP): post hoc analysis of LIBERTY ASTHMA QUEST",
        "Dupilumab efficacy in uncontrolled persistent asthma patients with history of comorbid chronic rhinosinusitis with or without nasal polyps",
        "Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 liberty asthma quest study",
        "Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high-and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study",
        "Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST",
        "Dupilumab improves FEV1and exacerbations in asthma with allergic rhinitis",
        "Dupilumab improves sinonasal symptoms of perennial allergic rhinitis (PAR) in uncontrolled persistent asthma patients with comorbid PAR",
        "Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma",
        "Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in liberty asthma quest",
        "Semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling of dupilumab on pre-bronchodilator forced expiratory volume in 1 second (FEV1) in uncontrolled moderate-to-severe asthma",
        "Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma",
        "Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis: results from a phase 2a trial",
        "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials",
        "Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils",
        "Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps",
        "Reslizumab decreases nasal adverse events and upper respiratory-associated concomitant medication use in patients with eosinophilic asthma and nasal polyps",
        "Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma",
        "Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled Analysis of the SIROCCO and CALIMA Trials",
        "Age-related differences in the pathogenesis of chronic rhinosinusitis",
        "Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis",
        "Saline irrigation for chronic rhinosinusitis",
        "Different types of intranasal steroids for chronic rhinosinusitis",
        "Nasal polyps: pathogenesis and treatment implications",
        "Endothelial L-selectin ligand expression in nasal polyps",
        "Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients",
        "Bias in meta-analysis detected by a simple, graphical test",
        "European position paper on rhinosinusitis and nasal polyps 2007",
        "European Position Paper on Rhinosinusitis and Nasal Polyps 2012",
        "CFR - Code of Federal Regulations Title 21",
        "The health impact of chronic sinusitis in patients seeking otolaryngologic care",
        "Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011",
        "Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019",
        "Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study",
        "Short-course oral steroids alone for chronic rhinosinusitis",
        "Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis",
        "Systemic and topical antibiotics for chronic rhinosinusitis",
        "Topical and systemic antifungal therapy for chronic rhinosinusitis",
        "Responsiveness and minimal clinically important difference for the EQ-5D in chronic rhinosinusitis",
        "Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review",
        "Psychometric validity of the 22-item Sinonasal Outcome Test",
        "CHronic Rhinosinusitis Outcome MEasures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis",
        "When to include clinical study reports and regulatory documents in systematic reviews",
        "Chronic rhinosinusitis with nasal polyps: insights into mechanisms of disease from emerging biological therapies",
        "Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis",
        "Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps",
        "Origin of nasal polyps: an endoscopic autopsy study",
        "Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide",
        "Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews",
        "Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179",
        "Cochrane Crowd: new ways of working together to produce health evidence",
        "The burden of revision sinonasal surgery in the UK\u2014data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study",
        "Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial",
        "Impact of chronic rhinosinusitis therapy on quality of life: a prospective randomized controlled trial",
        "Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis",
        "Living systematic reviews: 3. Statistical methods for updating meta-analyses",
        "Biologics in chronic rhinosinusitis: an update and thoughts for future directions",
        "Long-term revision rates for endoscopic sinus surgery",
        "RoB 2: a revised tool for assessing risk of bias in randomised trials",
        "Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps",
        "Living systematic reviews 2: combining human and machine effort",
        "Pathophysiology of chronic rhinosinusitis",
        "Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review",
        "Inflammation in chronic rhinosinusitis and nasal polyposis",
        "Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach",
        "Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease",
        "Chronic rhinosinusitis with and without nasal polyps is associated with decreased expression of glucocorticoid-induced leucine zipper",
        "Biologics for chronic rhinosinusitis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Norwich",
            "@id": "60117932",
            "affilname": "University of East Anglia, Norwich Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60117932",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "60025784",
            "affilname": "UK Cochrane Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025784",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "London",
            "@id": "60022176",
            "affilname": "National Institute for Health and Care Excellence (NICE)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022176",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "London",
            "@id": "60009797",
            "affilname": "Guy's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009797",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "115792440",
            "affilname": "Cochrane UK",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115792440",
            "affiliation-country": "United Kingdom"
        }
    ],
    "funding": [
        "Andrea Takeda",
        "Flemish Scientific Research Board",
        "Interuniversity Attraction Poles program",
        "Katie Webster",
        "American Geriatrics Society",
        "Genentech",
        "GlaxoSmithKline",
        "Sanofi",
        "Regeneron Pharmaceuticals",
        "National Institute for Health Research",
        "Ghent University"
    ]
}